Abstract
Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real-World Study H Nuslein,1 R Alten,2 M Galeazzi,3 HM Lorenz,4 MT Nurmohamed,5 WG Bensen,6 GR Burmester,7 H-H Peter,8 P Peichl,9 K Pavelka,10 M Chartier,11 C Poncet,12 C Rauch,13 M Le Bars14 1Internistische Schwerpunktpraxis, Nurnberg, Germany; 2Schlosspark-Klinik University Medicine, Berlin, Germany; 3University of Siena, Siena, Italy; 4University Hospital, Heidelberg, Germany; 5VU Univ Medical Center/Jan van Breeman Research Institute, Amsterdam, Netherlands; 6St Josephs Hospital and McMaster University, Hamilton, Canada; 7Charite-Universitatsmedizin, Berlin, Germany; 8University of Freiburg, Freiburg, Germany; 9Evangelisches Krankenhaus, Vienna, Austria; 10Institute of Rheumatology, Prague, Czech Republic; 11Chiltern International, Neuilly, France; 12Docs International, Nanterre, France; 13Bristol-Myers Squibb, Munich, Germany; 14Bristol-Myers Squibb, Rueil-Malmaison, France
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
